百奥泰: 百奥泰 2025年半年度报告摘要

Core Viewpoint - The report highlights the financial performance of Baotai Biopharmaceutical Co., Ltd. for the first half of 2025, indicating a growth in revenue but a significant loss in net profit compared to the previous year [1][2]. Financial Summary - Total assets at the end of the reporting period amounted to CNY 2,246.69 million, reflecting a 1.87% increase from the previous year [1]. - The net assets attributable to shareholders decreased by 17.65% to CNY 583.12 million compared to the previous year [1]. - Operating revenue reached CNY 441.89 million, representing a 9.84% increase year-on-year [1]. - The total profit for the period was a loss of CNY 124.77 million, an improvement from a loss of CNY 236.85 million in the same period last year [2]. - The net profit attributable to shareholders was a loss of CNY 124.93 million, compared to a loss of CNY 236.85 million in the previous year [2]. - The net profit after deducting non-recurring gains and losses was a loss of CNY 171.20 million, improving from a loss of CNY 270.33 million year-on-year [2]. - The net cash flow from operating activities was a negative CNY 0.81 million, a significant improvement from a negative CNY 63.26 million in the previous year [2]. - The weighted average return on net assets was -19.35%, an increase of 2.29 percentage points from -21.64% in the previous year [2]. - Basic and diluted earnings per share were both -CNY 0.57, compared to -CNY 0.30 in the previous year [2]. - Research and development expenses accounted for 78.94% of operating revenue, a decrease of 21.12 percentage points [2]. Shareholder Information - As of the end of the reporting period, the total number of shareholders was 9,481 [2]. - Major shareholders include Guangzhou Qixi Group Co., Ltd. with 38.64% ownership and Therabio International Limited with 11.39% ownership [3][4].